– FRANCE, Paris – BioSerenity, developer of solutions dedicated to personalized patient continuous care, today announced that Dassault Systèmes (EPA:DSY) participated as lead investor in a €65 million Series B financing.
BioSerenity develops a comprehensive and efficient health solution involving textiles equipped with sensors and online telehealth services to diagnose and monitor chronic pathologies.
Three of the first existing investors, BPI, Idinvest, and LBO, also participated in the round.
Dassault Systèmes will retain a seat on BioSerenity’s board of directors.
The funds will allow BioSerenity to accelerate the development of sensor-equipped wearables and associated telehealth solutions in the fields of cardiology, neurology, and sleep disorders. Automatic collection of clinical data made directly available to physicians, associated with online tools to diagnose and monitor chronic pathologies, represents a significant advance for affordable telemedicine.
The funds will be used to further develop BioSerenity’s solutions beyond their initial focus on cardiovascular, neurology, and sleep disorders, to grow its business internationally, and to develop new solutions for telemedicine.
“Healthcare industry growth will be led by connected medical devices offering possibilities to collect patient data in a cost-effective, continuous way that ensures patient adherence and comfort, and helps the medical community diagnose and treat conditions early on, paving the way for outcome-based care. This is precisely the purpose of BioSerenity,” said Claire Biot, Vice President, Life Sciences Industry, Dassault Systèmes. “For many years, Dassault Systèmes has been investing in building up the first end-to-end collaborative platform to accelerate innovation in the Life Sciences industry for the patient-centric experience.”
“With this new round of financing, we not only receive the means to pursue our growth, but we also reinforce our partnership with Dassault Systèmes, a company that is at the forefront of innovation in healthcare,” said Pierre-Yves Frouin, President, BioSerenity.
About BioSerenity
Founded in 2014 and headquartered in Paris, BioSerenity – which has been part of the 3DEXPERIENCE Lab – is developing wearable medical devices and digital point-of-care solutions that leverage textile innovation and artificial intelligence, as well as the electronic patient-reported outcome, internet of things and cloud technologies.
The startup provides hospitals and healthcare professionals with a portfolio of fully-operated care services. BioSerenity also provides pharmaceutical companies with turnkey solutions for companion diagnostics. This full-stack approach helps hospitals run acts less expensively and more efficiently, helps patients receive the right diagnosis faster, and supports treatment development and delivery with the collection of clinical and real-world data.
For more information: https://www.bioserenity.com/en/
About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE Company, provides business and people with virtual universes to imagine sustainable innovations. Its world-leading solutions transform the way products are designed, produced, and supported. Dassault Systèmes’ collaborative solutions foster social innovation, expanding possibilities for the virtual world to improve the real world. The group brings value to over 250,000 customers of all sizes, in all industries, in more than 140 countries.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
